Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ad.hIFN-β · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Ad.hIFN-β (BG00001, IDEC-201) | DRUG | - |
Inclusion Criteria: * Subjects with histologically confirmed hepatic metastases from primary colorectal carcinoma. * Not amenable to complete surgical resection for attempted cure as determined by the Principal Investigator (PI). * Tumor progression after prior therapy for colorectal carcinoma, inc...
Ad.hIFN-β is an investigational gene therapy being studied for the treatment of refractory colorectal carcinoma with liver metastases. It was evaluated in a Phase 1 trial in patients whose colorectal cancer had spread to the liver and had not responded to prior treatment.
Ad.hIFN-β is being developed by Biogen Inc., which trades on the Nasdaq under the ticker BIIB. The company sponsored the Phase 1 study of the agent in refractory colorectal carcinoma with liver metastases.
Ad.hIFN-β is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
Ad.hIFN-β was studied in one completed Phase 1 trial, NCT00107861, titled Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases. The trial enrolled 44 patients in the United States and was an uncontrolled study without randomization or blinding.
Yes. Ad.hIFN-β is also known as BG00001 and IDEC-201. These names refer to the same investigational agent developed by Biogen for refractory colorectal carcinoma with liver metastases.